Molecular abnormalities associated with endocrine tumors of the uterine cervix

I I Wistuba1, B Thomas, C Behrens

  • 1Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas.

Gynecologic Oncology
|January 16, 1999
PubMed

Insights

Endocrine cervical tumors show distinct molecular profiles, combining features of lung neuroendocrine tumors and cervical squamous cell carcinomas. Key findings include human papillomavirus (HPV) presence and TP53 gene mutations.

Area of Science:

  • Gynecologic Oncology
  • Molecular Pathology
  • Cancer Genetics

Background:

  • Endocrine tumors of the uterine cervix are rare and their molecular pathogenesis is not fully understood.
  • Understanding these molecular abnormalities is crucial for diagnosis and treatment strategies.

Purpose of the Study:

  • To investigate the molecular abnormalities in endocrine tumors of the uterine cervix.
  • To identify specific genetic alterations and their potential role in tumor development.

Main Methods:

  • DNA analysis of 15 archival endocrine cervical tumors (carcinoids, large cell neuroendocrine carcinomas, small cell carcinomas).
  • Detection of human papillomavirus (HPV) sequences (types 16, 18, 31, 33).
  • Analysis of TP53 and K-ras gene mutations and loss of heterozygosity (LOH) at key chromosomal regions.

Main Results:

  • HPV sequences were found in 53% of tumors, with HPV 16 and 18 being detected.
  • Frequent LOH at 9p21 (43%) and 3p deletions (47%) were observed.
  • TP53 gene mutations occurred in 47% of tumors, often concurrently with HPV sequences; K-ras mutations were absent.

Conclusions:

  • Endocrine cervical tumors exhibit a unique molecular signature.
  • These tumors share molecular features with both lung neuroendocrine tumors (TP53 abnormalities, 9p21 deletions) and cervical squamous cell carcinomas (HPV, 3p deletions).

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Cellular Adaptation IV: Dysplasia and Metaplasia01:24

Cellular Adaptation IV: Dysplasia and Metaplasia

DysplasiaDysplasia refers to abnormal changes in the size, shape, and organization of mature cells, characterized by pleomorphism, nuclear abnormalities, and increased mitotic activity. It commonly affects epithelial tissues, including the cervix, gastrointestinal tract, respiratory mucosa, and endometrium. Although it may occur alongside hyperplasia, dysplasia is not a true adaptive response but a preneoplastic change with potential to progress to cancer.When confined above the basement...